InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - ETF Exposure

Current share price for TLX : $15.650 0.07 (0.45%)+

Telix Pharmaceuticals Limited (TLX) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a global biopharmaceutical company engaged in the development and commercialization of targeted therapeutic and diagnostic radiopharmaceuticals, along with supporting medical technologies. Headquartered in Melbourne, Australia, Telix maintains strategic international operations across the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan.

TLX General Information +

ASX Code TLX
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 5,317
TLX Share Price $15.650
Day High $16.150
Day Low $15.620
Last Close $15.580
TLX Share Price Movement $0.07 ( 0.45% )
Prices as at 16:40, 28 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to TLX

As a significant Australian company by market capitalisation, TLX is held across 23 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when TLX moves, funds like IMPQ, M1DS, MVE, FAIR and VSO that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 4% to TLX , while the average exposure across all 23 ETFs that hold it is around 0.6% .

Top ETF holdings

Last updated: ETF data and holdings as at 28 August 2026

Own TLX directly or through an ETF?

How does holding Telix Pharmaceuticals Limited (TLX) shares directly compare to ETFs that include it?

TLX Direct
IMPQ
ASX 		M1DS
CBOE 		MVE
ASX 		FAIR
ASX 		VSO
ASX
Holdings 1 company 41 holdings 51 holdings 50 holdings 83 holdings 194 holdings
TLX Weight 100% 4% 2% 1.3% 0.9% 0.8%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 0.89% p.a. - 0.45% p.a. 0.49% p.a. 0.3% p.a.
Approx. Yield - 2.16% - 2.51% 3.04% 4.63%
Star Ratings - star star starstarstarstar starstarstarstar starstarstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not TLX's direct yield. Annual cost uses each ETF's MER.

TLX Exposure on $10,000 investment

How a $10,000 investment in Telix Pharmaceuticals Limited (TLX) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Telix Pharmaceuticals Limited (TLX) Direct share $15.650 0.19% +$19 $10,019
eInvest Better Future (Managed Fund) (IMPQ) Equity - Australia Small/Mid Cap $4.160 -3.48% -$348 $9,652
Paradice Australian Mid Cap Fund Active ETF (M1DS) Equity - Australia Strategy $6.480 1.09% +$109 $10,109
VanEck S&P/ASX MidCap ETF (MVE) Equity - Australia Small/Mid Cap $46.270 1.56% +$156 $10,156
BetaShares Australian Sustainability Leaders ETF (FAIR) Equity - Australia Strategy $19.000 -0.26% -$26 $9,974
Vanguard MSCI Australian Small Companies Index ETF (VSO) Equity - Australia Small/Mid Cap $75.510 0.25% +$25 $10,025

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Telix Pharmaceuticals Limited (TLX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Telix Pharmaceuticals Limited (TLX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Telix Pharmaceuticals Limited (TLX) price-sensitive announcements

TLX - Telix HY26 Results Presentation
Telix Pharmaceuticals Limited's HY26 results presentation highlights strong financial perf
Telix Pharmaceuticals Limited (TLX)
20 Aug 2026 | 8:42 AM
TLX - Telix HY26 Results Announcement
Telix Pharmaceuticals Limited reported strong financial results for the first half of 2026
Telix Pharmaceuticals Limited (TLX)
20 Aug 2026 | 8:41 AM
TLX - Telix HY26 Appendix 4D and Interim Report
Telix Pharmaceuticals Limited has reported significant financial growth for the half-year
Telix Pharmaceuticals Limited (TLX)
20 Aug 2026 | 8:40 AM
TLX - Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress
Telix Pharmaceuticals Limited announced strong financial results for Q2 2026, reporting a
Telix Pharmaceuticals Limited (TLX)
21 Jul 2026 | 8:26 AM

Telix Pharmaceuticals Limited (TLX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
 Health Care $5,318 Telix HY26 Results Presentation 20 Aug 2026 8:42AM $16.840 $15.650 fallen by 7.07%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
 Health Care $5,318 Telix HY26 Results Announcement 20 Aug 2026 8:41AM $16.840 $15.650 fallen by 7.07%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
 Health Care $5,318 Telix HY26 Appendix 4D and Interim Report 20 Aug 2026 8:40AM $16.840 $15.650 fallen by 7.07%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
 Health Care $5,318 Telix H1 2026 Results - Investor Webcast Notification 31 Jul 2026 8:30AM $14.070 $15.650 risen by 11.23%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
 Health Care $5,318 Change in substantial holding 24 Jul 2026 8:21AM $15.170 $15.650 risen by 3.16%
Telix Pharmaceuticals Limited (TLX)
ORDINARY FULLY PAID
 Health Care $5,318 Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress 21 Jul 2026 8:26AM $15.100 $15.650 risen by 3.64%

TLX Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025F $122.66 $34.57 61.00% 82.53 0.00 0.00% 0.0%
2024F $76.18 $21.47 5.70% 132.88 0.00 0.00% 0.0%
2023A $65.73 $20.31 -174.80% 46.74 0.00 0.00% 0.0%

TLX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 F 2025 F 2023 A 2024 F 2025 F 2023 A 2024 F 2025 F
CSL Limited (CSL) $83,273M 0.7309 -0.4384 0.0505 10.7722 19.1821 18.2601 2.44% 2.42% 2.50%
Clinuvel Pharmaceuticals Limited (CUV) $463M 0.0287 0.0000 0.0000 12.7855 0.0000 0.0000 0.54% 0.00% 0.00%
Immutep Limited (IMM) $74M 0.1854 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $3,130M -0.4380 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,294M -1.3893 0.0000 -0.9100 0.0000 147.5379 1,640.0000 0.00% 0.00% 0.00%

TLX Directors

Name Position Start Date
Dr Christian Peter Behrenbruch Chief Executive Officer, Managing Director 3 Jan 2017
Ms Jann E Skinner Non-Executive Director 19 Jun 2018
Ms Marie Elizabeth McDonald Non-Executive Director 3 Mar 2025
Mr David Gill Non-Executive Director 11 May 2026
Dr Maria Rivas Non-Executive Director 11 May 2026
Mr William (Bill) Jellison Non-Executive Director 11 May 2026
Dr Mark Alexander Nelson Non-Executive Director, Interim Chairman 17 Sep 2017

Telix Pharmaceuticals Limited (TLX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
11 Jun 2026 GILL, David Buy Direct Shares 10,200 $9.434 $96,221.700
29 Apr 2026 BEHRENBRUCH, Christian Buy Indirect Shares 67,935 $14.671 $996,699.480
5 Nov 2025 BEHRENBRUCH, Christian Exercise Options 100,708 $4.380 $441,101.000

See all changes in directors' interest & trades for Telix Pharmaceuticals Limited (TLX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TLX Management

Name Position
Raphael Ortiz Chief Executive Officer, Telix International
Kevin Richardson Chief Executive Officer, Telix Precision Medicine
Richard Valeix Chief Executive Officer, Telix Therapeutics
Darren Smith Group Chief Financial Officer
David Cade Group Chief Medical Officer
Mary Jessel Group Chief of Clinical Affairs
Darren Patti Group Chief Operating Officer
Lena Moran-Adams Group General Counsel
Shomalin Naidoo Interim Company Secretary
Meredith Crowe Senior Vice President, People & Culture

TLX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Telix Pharmaceuticals Limited (TLX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
28,187,775 (8.30%) State Street Corporation and subsidiaries
22,419,015 (6.60%) JPmorgan Chase & Co. and its affiliates
20,675,000 (6.10%) Gnosis Verwaltungsgesellschaft
20,675,000 (6.10%) Elk River Holdings Pty Ltd

TLX Calendar of Events

Date Event
19 August 2027 Report (Interim)
19 February 2027 Report (Annual)
19 February 2027 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.